Bausch Health Companies Inc. (NYSE:BHC) has been assigned a consensus rating of “Buy” from the twelve analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $33.38.
Several equities research analysts have recently issued reports on BHC shares. Royal Bank of Canada decreased their price objective on Bausch Health Companies from $41.00 to $40.00 and set an “outperform” rating on the stock in a report on Wednesday, November 3rd. Jefferies Financial Group reiterated a “buy” rating on shares of Bausch Health Companies in a report on Friday, October 1st. BMO Capital Markets reiterated a “hold” rating on shares of Bausch Health Companies in a report on Monday, November 8th. Finally, Zacks Investment Research upgraded Bausch Health Companies from a “hold” rating to a “buy” rating and set a $29.00 target price on the stock in a report on Tuesday, January 4th.
In other news, Director Steven D. Miller purchased 50,000 shares of the firm’s stock in a transaction on Tuesday, November 30th. The stock was bought at an average cost of $24.24 per share, for a total transaction of $1,212,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 13.75% of the company’s stock.
Shares of BHC stock traded down $0.04 during trading hours on Friday, reaching $26.71. 272,602 shares of the company’s stock were exchanged, compared to its average volume of 3,871,358. The company has a market cap of $9.58 billion, a P/E ratio of -8.27, a price-to-earnings-growth ratio of 0.48 and a beta of 1.64. The company’s 50 day moving average is $26.22 and its two-hundred day moving average is $27.60. Bausch Health Companies has a 1 year low of $22.99 and a 1 year high of $34.80.
Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Tuesday, November 2nd. The company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.07. Bausch Health Companies had a negative return on equity of 2,440.75% and a negative net margin of 13.85%. The company had revenue of $2.11 billion during the quarter, compared to the consensus estimate of $2.15 billion. Sell-side analysts forecast that Bausch Health Companies will post 4.23 EPS for the current fiscal year.
About Bausch Health Companies
Bausch Health Cos., Inc engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products.
Featured Article: What is dividend yield?
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.